Winner Profile
Fangwen Shuai
CEO, Hunan ER-KANG Pharmaceutical
Industry: Pharmaceuticals
Company size: Medium
Published: 2016-10-17
Is Hunan ER-KANG Pharmaceutical a good stock investment?
Based on the annual Obermatt CEO of the Year analysis, Fangwen Shuai (Hunan ER-KANG Pharmaceutical) earned the following Obermatt pins for the management performance.
Obermatt accolades Fangwen Shuai
Fangwen Shuai was included in the competition among China Top 100 Growth Companies (China) (current winners). See the winners of the other competitions or how the CEOs performed over all competitions.
Performance Overview Fangwen Shuai
In summary, Fangwen Shuai obtained the following achievements in the individual Obermatt categories by participating in the Obermatt rankings (averages of all evaluated rankings are shown for this CEO, also for other companies):
CEO performance is displayed relative to that of other CEOs that competed in the same categories for the same number of competitions. A ranking of 94 in Combined Performance indicates that Fangwen Shuai was better than 94% of all other CEOs that were analyzed as part of the China Top 100 Growth Companies – China for three participations in Obermatt CEO competitions. Fangwen Shuai’s average ranking can be found in the Multi-Year Rankings for China Top 100 Growth Companies - China.